Long-term safety / tolerability of paliperidone extended-release tablets: 52-week.

1 Kramer M, Simpson G, Kushner S, et al, Long-term safety / tolerability of paliperidone extended-release tablets: 52-week, open-label, extension stage one. Symptom schizophrenia relapse prevention study, December 2007.

Ortho-McNeil Janssen Scientific Affairs, LLC and Johnson & Johnson Pharmaceutical Research & Development, LLC sponsored this clinical study. Janssen, markets INVEGA characterized by positive symptoms , each company in the USA , a subsidiary of Johnson & Johnson. For more details about the study are available on request.The supply monitoring diagnostic, minor modifications to ST segment continuously and precisely captured and recorded, and be retrieved the physician during patient treatment check aftercare examinations, since lot cardiac series are transitory, continuous ST Monitoring is important as allows physicians comprehensive ST segment information about time more likely as sporadic diagnostic reports, when the patient is in clinic or hospital.